

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

A.J.
see B.A.

1. (Currently Amended) A method of treatment of an existing human papillomavirus (HPV) infection comprising: administering a therapeutic vaccine^{inducing cellular response} comprising [[PV]] HPV VLPs selected from the group consisting of [[PV]] HPV L1 VLPs and [[PV]] HPV L1/L2 VLPs to a patient suffering from the [[PV]] HPV infection characterized in that said therapeutic vaccine excludes [[PV]] HPV E protein.

2. (Currently Amended) The method of treatment according to claim 1, wherein the [[PV]] HPV infection is characterized by the presence of epithelial lesions.

3. (Previously Presented) The method of treatment according to claim 2, wherein the epithelial lesions are selected from the group consisting of palmar warts, planter warts, anogenital warts, flat and planar warts of the skin and mucosal surfaces, CIN, ~~equine sarcoid~~ and replicating or vegetative PV infection.

A.J.
see
B.A.

4. (Previously Presented) The method of treatment according to claim 3, wherein the epithelial lesions are genital warts caused by HPV 6, 11, 34, 39, 41, 42, 43, 44, 51, 52, 53, 54 or 55.

5. (Previously Presented) The method of treatment according to claim 4, wherein the genital warts are caused by HPV 6 and HPV 11.

6. (Withdrawn) A method of producing a PV VLP comprising: (a) cloning one or more PV VLP genes into a vector and (b) expressing the one or more PV VLP genes in an eukaryotic cell transduced by the vector.

7. (Withdrawn) The method according to claims 1-5, further comprising: cloning the PV L1 or PV L2 gene into a vector and expressing the PV L1 or PV L2 gene in a host cell.

8. (Withdrawn) The method according to claim 6, wherein the one or more PV VLP genes comprise (i) a PV L1 VLP gene or (ii) a PV L1 VLP gene and a PV L2 VLP gene,